LAUSANNE, Switzerland, October 4, 2021 / PRNewswire / – Debiopharm (www.debiopharm.com), a global biopharmaceutical company based in Switzerland, today announced the two winners of the 17e JCA Mauvernay annual award for groundbreaking Japanese oncology research projects in 2 categories: Innovative and / or disruptive research – Dr. Shumpei Ishikawa and translational research – Dr. Hiromichi ebi. The winners were honored with trophies and a cash prize in the ’80s (virtual / live) hybrid encountere Japanese Cancer Association (JCA) Annual Meeting on saturday 2 octobersd in Yokohama, Japan by Prof. Hideyuki Saya President of the JCA and Dr. Takato Noumi, representative of Debiopharm in Japan as well as Thierry Mauvernay, Chairman of Debiopharm, Bertrand Ducrey CEO of Debiopharm who joined virtually.
“Japan and Switzerland share several common values such as a commitment to excellence and professional diligence. This is one of the reasons why I believe that Japanese research continues to excel and exceed our expectations, ”said Thierry Mauvernay, President of Debiopharm. “It is an honor for us to recognize these two new winners of the JCA Mauvernay Prize and to realize what their early research could mean for patients in the future through further development.”
“We were impressed with the potential implications of Dr Ishikawa and Dr Ebi in different types of cancer. Cancer remains the leading cause of death in the world, so it deserves deep exploration by great minds in order to get closer to a cure. Japanese cancer researchers continue to capture the attention of the international community, as several of the past Nobel Prize winners have shown. We are therefore very happy to continue to win this important award and hope to spark new collaborations ”, explained Bertrand Ducrey, CEO of Debiopharm.
Dr. Shumpei Ishikawa Disruptive research at the University of Toyko, offers new insights into an aggressive form of gastric cancer, diffuse gastric carcinoma (DGC), by exploring the genomic characterization of the cancer life cycle. His comprehensive characterization of DGC includes the identification of genes that cause cells to transform into cancer cells (oncogenes), molecular and cellular dissection of the tumor microenvironment, and environmental factors contributing to disease. This holistic approach has led to several influential findings that have been published in leading scientific journals.
Dr. Hiromichi ebi Translational research at the Aichi Cancer Research Center Research Institute examines the development of targeted therapies against tumors with aberrant MAPK signaling. His work focuses on elucidating the molecular mechanisms underlying the differential clinical activities of drugs targeting mutated oncogenes depending on cancer tissue and tumor microenvironment.
The JCA-Mauvernay Prize
Since 2005, the Japanese Cancer Association (JCA) and Debiopharm Group have co-organized the “JCA-Mauvernay Award”. This prize illustrates the curiosity that drives researchers as well as the scientific cooperation between Japan and Switzerland. It aims to recognize outstanding achievements in the field of oncology among Japanese researchers, both in fundamental and clinical aspects. The prize has a total value of CHF 25,000.
Debiopharm’s commitment to patients
Debiopharm develops innovative therapies that target significant unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and actual patient reach, we identify compounds and technologies with high potential for licensing, clinically demonstrate their safety and efficacy, and then select major pharmaceutical marketing partners for maximize patient access globally.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews on http://twitter.com/DebiopharmNews
Responsible for the communication
Phone: +41 (0) 21 321 01 11
SOURCE Debiopharm International SA